Interview with the CEO of LIDDS, Anders Månsson

LIDDS is a Swedish drug delivery company specializing in depot formulations for intratumoral injections with its NanoZolid technology. This allows for effective dose delivery while minimizing systemic side effects, an important feature in oncology. LIDDS focuses on early-stage partnership with pharmaceutical companies, for new and established APIs, and also does proprietary drug development for out-licensing in preclinical or clinical phases.